Follicum receives European patent for the company's peptides for developing first in class diabetes treatments
Follicum AB today announces that the European Patent Office (EPO) has approved the patent EP 3 618 845 B1, which refers to the company's novel peptides that are being developed to treat diabetes. The approval follows the previous provisional approval by the EPO announced on March 20, 2020.
The approval by the EPO of patent No. EP 3,618,845 B1 provides protection for the company's peptides and their use to treat diabetes in Europe until 2038.
Similar patents have previously been approved in the United States. In addition, Follicum has a corresponding patent application under review by authorities in China, Japan, India, Canada, South Korea, Singapore, Israel and Australia.
"It is a declaration of strength that the world's two largest patent offices, USPTO and EPO, have now approved Follicum's patents in the field of diabetes therapy. This provides stable and robust protection for our product candidates and their use," says Follicum's CEO, Jan Alenfall.
Diabetes is rapidly increasing globally. The disease is characterized by poor blood sugar control due to defective insulin signalling, which causes serious sequelae such as cardiovascular disease, renal failure, obesity, blindness and diabetic foot ulcers. Diabetes as well as its accompanying illnesses represent a major burden, partly for the individual patient, but also for the entire health care system. There is thus an already large and growing global need for new therapies that address effective control of glucose levels in combination with preventive effects on the various diabetic complications.
For further information, please contact:
Jan Alenfall – CEO, Follicum AB
Phone: +46 (0)709 31 51 15
About Follicum AB
Follicum AB (Publ. - Spotlight: FOLLI) develops drug candidates based on tissue reparing peptides with potential use in several therapeutic areas. The company’s primary candidate, FOL-005 for stimulating hair growth, is currently being evaluated in a phase IIa study in collaboration with internationally reputable specialist clinics. The company’s project in diabetes aims at protecting insulin producing cells against damage and thereby reducing the risk of complications. Based on promising preclinical results preparations for entering a phase I study is ongoing, which expects to be initiated in 2021. Both projects have the potential to become so called first-in-class drugs. For more information, please visit www.follicum.com.
Issuance of a 5th tranche of 3 millions EUR of notes convertible into new shares
DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company pioneering the exploration and exploitation of bacterial biodiversity to address the urgent and global challenge of antimicrobial resistance, announces today the issuance of a 5th tranche of notes convertible into new shares (the "OCA"...
Emission d’une 5ème tranche d'OCA de 3 m€
DEINOVE (Euronext Growth Paris : ALDEI), société de biotechnologie française pionnière dans l’exploration et l'exploitation de la biodiversité bactérienne pour relever le défi urgent et planétaire de la résistance aux antimicrobiens, annonce ce jour l'émission d'une 5ème tranche d'obligations conver...
Surgical Science announces intention to carry out a directed share issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. PL...
Surgical Science offentliggör avsikt att genomföra en riktad nyemission
EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, KANADA, JAPAN ELLER NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV INFORMATIONEN SKULLE VARA I STRID MED GÄLLANDE REGLER ELLER KRÄVA REGI...